Peripheral artery surgery – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 04:12:32 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Peripheral artery surgery – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effect of Clopidogrel and Acetylsalicylic Acid on Reducing Heart and Blood Vessel Events in Patients with Peripheral Arterial Disease https://clinicaltrials.eu/trial/study-on-the-effect-of-clopidogrel-and-acetylsalicylic-acid-on-reducing-heart-and-blood-vessel-events-in-patients-with-peripheral-arterial-disease/ Wed, 29 Apr 2026 15:01:35 +0000 https://clinicaltrials.eu/trial/study-on-the-effect-of-clopidogrel-and-acetylsalicylic-acid-on-reducing-heart-and-blood-vessel-events-in-patients-with-peripheral-arterial-disease/ This clinical trial is focused on studying the effects of different treatments for Peripheral Arterial Disease (PAD), a condition where the blood vessels in the legs are narrowed, reducing blood flow. The study will compare two types of treatments: single antiplatelet therapy using Clopidogrel and dual antiplatelet therapy using both Clopidogrel and Acetylsalicylic Acid (commonly known as aspirin). These medications help prevent blood clots, which can improve blood flow and reduce the risk of serious complications.

The purpose of the study is to determine if using both medications together is more effective than using just one in reducing the risk of serious health events, such as heart attacks or strokes, in patients with PAD who have undergone a procedure called endovascular revascularization. This procedure is used to open up blocked blood vessels in the legs. Participants in the study will be randomly assigned to receive either the single or dual therapy, or a placebo, which is a tablet that looks like the medication but does not contain any active ingredients.

The study will last for up to 12 months, during which participants will take the assigned treatment orally in the form of tablets. Throughout the study, the health of the participants will be monitored to track any occurrences of serious health events, such as death from any cause, major cardiovascular events, or major limb events. The study will also look at the occurrence of bleeding and other side effects. By the end of the study, researchers hope to better understand the benefits and risks of these treatments for people with PAD.

]]>